These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18217249)

  • 21. Drug delivery strategies for Alzheimer's disease treatment.
    Di Stefano A; Iannitelli A; Laserra S; Sozio P
    Expert Opin Drug Deliv; 2011 May; 8(5):581-603. PubMed ID: 21391862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unraveling the tangled brain of Alzheimer's.
    Wolfson W
    Chem Biol; 2008 Feb; 15(2):89-90. PubMed ID: 18291309
    [No Abstract]   [Full Text] [Related]  

  • 23. Secretases as therapeutic targets for Alzheimer's disease.
    Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pivotal trials for β-secretase inhibitors in Alzheimer's.
    Sheridan C
    Nat Biotechnol; 2015 Feb; 33(2):115-6. PubMed ID: 25658256
    [No Abstract]   [Full Text] [Related]  

  • 25. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
    Trechot P; Schmutz JL
    Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
    [No Abstract]   [Full Text] [Related]  

  • 26. Deal watch: Lilly buys back into the BACE race for Alzheimer's disease.
    Cully M
    Nat Rev Drug Discov; 2014 Nov; 13(11):804. PubMed ID: 25323931
    [No Abstract]   [Full Text] [Related]  

  • 27. The pulse of drug development for Alzheimer's disease.
    Rafii MS
    Rev Recent Clin Trials; 2010 Jan; 5(1):57-62. PubMed ID: 20205688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach.
    Calzà L; Baldassarro VA; Giuliani A; Lorenzini L; Fernandez M; Mangano C; Sivilia S; Alessandri M; Gusciglio M; Torricella R; Giardino L
    Curr Top Med Chem; 2013; 13(15):1843-52. PubMed ID: 23931439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores - development of potential agents for the treatment of Alzheimer's disease.
    Linning P; Haussmann U; Beyer I; Weidlich S; Schieb H; Wiltfang J; Klafki HW; Knölker HJ
    Org Biomol Chem; 2012 Oct; 10(41):8216-35. PubMed ID: 22930158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of arylquinones as BACE1 inhibitors, β-amyloid peptide aggregation inhibitors, and destabilizers of preformed β-amyloid fibrils.
    Ortega A; Rincón Á; Jiménez-Aliaga KL; Bermejo-Bescós P; Martín-Aragón S; Molina MT; Csákÿ AG
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2183-7. PubMed ID: 21441028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Structure and function analysis of gamma-secretase complex toward development of therapeutics for Alzheimer's disease].
    Tomita T
    Tanpakushitsu Kakusan Koso; 2009 Sep; 54(12 Suppl):1684-9. PubMed ID: 21089607
    [No Abstract]   [Full Text] [Related]  

  • 32. Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.
    Close J; Heidebrecht R; Hendrix J; Li C; Munoz B; Surdi L; Kattar S; Tempest P; Moses P; Geng X; Hughes B; Smotrov N; Moxham C; Chapnick J; Kariv I; Nikov G; Burke JE; Deshmukh S; Jeliazkova-Mecheva V; Leach JK; Diaz D; Xu L; Yang Z; Kwei G; Moy L; Shah S; Tanga F; Kenefic C; Savage D; Shearman M; Ball RG; McNevin MJ; Markarewicz A; Miller T
    Bioorg Med Chem Lett; 2012 May; 22(9):3203-7. PubMed ID: 22483609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine].
    Schwalbe O; Wunderlich S; Kloft C
    Med Monatsschr Pharm; 2006 Jun; 29(6):222-4. PubMed ID: 16792199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
    Hussain I
    IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why is it important to be able to detect the presence of beta-amyloid in the brain at an early stage in Alzheimer's, and what can be done to prevent its growth?
    Health News; 2004 Sep; 10(9):16. PubMed ID: 15597459
    [No Abstract]   [Full Text] [Related]  

  • 36. [Biology and pathobiology of the intramembrane proteolysis by gamma-secretase].
    Tomita T
    Tanpakushitsu Kakusan Koso; 2009 Oct; 54(13):1747-53. PubMed ID: 19827607
    [No Abstract]   [Full Text] [Related]  

  • 37. Saving the mind faces high hurdles.
    Travis J
    Science; 2005 Jul; 309(5735):731. PubMed ID: 16051787
    [No Abstract]   [Full Text] [Related]  

  • 38. Progress toward a practical BACE-1 inhibitor.
    Hills ID; Vacca JP
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):383-91. PubMed ID: 17659479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress toward the discovery and development of efficacious BACE inhibitors.
    Durham TB; Shepherd TA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular pathology and therapeutics in Alzheimer's disease: amyloid beta-protein as a therapeutic target].
    Ohyagi Y
    Fukuoka Igaku Zasshi; 2006 Sep; 97(9):261-8. PubMed ID: 17134029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.